Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.

Melchardt T, Magnes T, Hufnagl C, Thorner AR, Ducar M, Neureiter D, Tränkenschuh W, Klieser E, Gaggl A, Rösch S, Rasp G, Hartmann TN, Pleyer L, Rinnerthaler G, Weiss L, Greil R, Egle A.

Eur J Cancer. 2018 Apr;93:69-78. doi: 10.1016/j.ejca.2018.01.064. Epub 2018 Mar 20.

PMID:
29477794
2.

Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.

Gutjahr JC, Szenes E, Tschech L, Asslaber D, Schlederer M, Roos S, Yu X, Girbl T, Sternberg C, Egle A, Aberger F, Alon R, Kenner L, Greil R, Orian-Rousseau V, Hartmann TN.

Blood. 2018 Mar 22;131(12):1337-1349. doi: 10.1182/blood-2017-08-802462. Epub 2018 Jan 19.

3.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A.

J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.

4.

TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.

Catakovic K, Gassner FJ, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M, Steiner M, Gutjahr JC, Pleyer L, Egle A, Hartmann TN, Greil R, Geisberger R.

Oncoimmunology. 2017 Sep 21;7(1):e1371399. doi: 10.1080/2162402X.2017.1371399. eCollection 2017.

5.

The sound of tumor cell-microenvironment communication - composed by the Cancer Cluster Salzburg research network.

Wessler S, Aberger F, Hartmann TN.

Cell Commun Signal. 2017 Jun 2;15(1):20. doi: 10.1186/s12964-017-0176-z. No abstract available.

6.

Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling.

Aberger F, Hutterer E, Sternberg C, Del Burgo PJ, Hartmann TN.

Cell Commun Signal. 2017 Jan 25;15(1):8. doi: 10.1186/s12964-017-0163-4. Review.

7.

Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.

Greil R, Hutterer E, Hartmann TN, Pleyer L.

Cell Commun Signal. 2017 Jan 19;15(1):5. doi: 10.1186/s12964-016-0155-9. Review.

8.

Epidermal-specific deletion of CD44 reveals a function in keratinocytes in response to mechanical stress.

Shatirishvili M, Burk AS, Franz CM, Pace G, Kastilan T, Breuhahn K, Hinterseer E, Dierich A, Bakiri L, Wagner EF, Ponta H, Hartmann TN, Tanaka M, Orian-Rousseau V.

Cell Death Dis. 2016 Nov 10;7(11):e2461. doi: 10.1038/cddis.2016.342.

9.

BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia.

Haerzschel A, Catusse J, Hutterer E, Paunovic M, Zirlik K, Eibel H, Krenn PW, Hartmann TN, Burger M.

Ann Hematol. 2016 Dec;95(12):1979-1988. Epub 2016 Aug 20.

10.

CD44: More than a mere stem cell marker.

Morath I, Hartmann TN, Orian-Rousseau V.

Int J Biochem Cell Biol. 2016 Dec;81(Pt A):166-173. doi: 10.1016/j.biocel.2016.09.009. Epub 2016 Sep 15. Review.

PMID:
27640754
11.

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Letter.

Zucchetto A, Tissino E, Hartmann TN, Chigaev A, Del Poeta G, Colombatti A, Gattei V.

Clin Cancer Res. 2016 Jul 1;22(13):3410-1. doi: 10.1158/1078-0432.CCR-16-0050. No abstract available.

12.

Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.

Melchardt T, Hufnagl C, Weinstock DM, Kopp N, Neureiter D, Tränkenschuh W, Hackl H, Weiss L, Rinnerthaler G, Hartmann TN, Greil R, Weigert O, Egle A.

Oncotarget. 2016 Aug 9;7(32):51494-51502. doi: 10.18632/oncotarget.9860.

13.

ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia.

Krenn PW, Hofbauer SW, Pucher S, Hutterer E, Hinterseer E, Denk U, Asslaber D, Ganghammer S, Sternberg C, Neureiter D, Aberger F, Wickström SA, Egle A, Greil R, Hartmann TN.

Cancer Res. 2016 Apr 15;76(8):2186-96. doi: 10.1158/0008-5472.CAN-15-3379. Epub 2016 Feb 2.

14.

Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors.

Ganghammer S, Gutjahr J, Hutterer E, Krenn PW, Pucher S, Zelle-Rieser C, Jöhrer K, Wijtmans M, Leurs R, Smit MJ, Gattei V, Greil R, Hartmann TN.

Haematologica. 2016 Mar;101(3):e99-102. doi: 10.3324/haematol.2015.133470. Epub 2015 Nov 20. No abstract available.

15.

CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model.

Kocher T, Asslaber D, Zaborsky N, Flenady S, Denk U, Reinthaler P, Ablinger M, Geisberger R, Bauer JW, Seiffert M, Hartmann TN, Greil R, Egle A, Piñón Hofbauer J.

Leukemia. 2016 Jun;30(6):1409-13. doi: 10.1038/leu.2015.307. Epub 2015 Nov 2. No abstract available.

16.

Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?

Benedetti D, Tissino E, Caldana C, Dal Bo M, Bomben R, Marconi D, Ganghammer S, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Del Poeta G, VanMeter A, Zucchetto A, Espina V, Liotta L, Gattei V.

Leukemia. 2016 Feb;30(2):513-7. doi: 10.1038/leu.2015.149. Epub 2015 Jun 19. No abstract available.

PMID:
26183532
17.

The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells.

Hofbauer SW, Krenn PW, Piñόn Hofbauer J, Pucher S, Asslaber D, Egle A, Hartmann TN, Greil R.

Br J Haematol. 2016 Mar;172(5):815-9. doi: 10.1111/bjh.13542. Epub 2015 Jul 6. No abstract available.

18.

The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia.

Gutjahr JC, Greil R, Hartmann TN.

Front Immunol. 2015 Apr 20;6:177. doi: 10.3389/fimmu.2015.00177. eCollection 2015. Review.

19.

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.

Gassner FJ, Zaborsky N, Catakovic K, Rebhandl S, Huemer M, Egle A, Hartmann TN, Greil R, Geisberger R.

Br J Haematol. 2015 Aug;170(4):515-22. doi: 10.1111/bjh.13467. Epub 2015 May 4.

20.

B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia.

Zaborsky N, Holler C, Geisberger R, Asslaber D, Gassner FJ, Egger V, Piñón-Hofbauer J, Kocher T, Hartmann TN, Greil R, Egle A.

Haematologica. 2015 Aug;100(8):e307-10. doi: 10.3324/haematol.2015.124719. Epub 2015 Apr 24. No abstract available.

21.

CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.

Ganghammer S, Hutterer E, Hinterseer E, Brachtl G, Asslaber D, Krenn PW, Girbl T, Berghammer P, Geisberger R, Egle A, Zucchetto A, Kruschinski A, Gattei V, Chigaev A, Greil R, Hartmann TN.

Oncotarget. 2015 May 20;6(14):12048-60.

22.

Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.

Merkel O, Hamacher F, Griessl R, Grabner L, Schiefer AI, Prutsch N, Baer C, Egger G, Schlederer M, Krenn PW, Hartmann TN, Simonitsch-Klupp I, Plass C, Staber PB, Moriggl R, Turner SD, Greil R, Kenner L.

J Pathol. 2015 Aug;236(4):445-56. doi: 10.1002/path.4539. Epub 2015 Apr 27.

23.

Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia.

Kern D, Regl G, Hofbauer SW, Altenhofer P, Achatz G, Dlugosz A, Schnidar H, Greil R, Hartmann TN, Aberger F.

Oncogene. 2015 Oct 16;34(42):5341-51. doi: 10.1038/onc.2014.450. Epub 2015 Feb 2.

24.

VLA-4 and CXCR4 overexpression in bone marrow of an aleukemic B-cell acute lymphoblastic leukemia presenting with osteolytic bone lesions.

Hinterseer E, Stiefel O, Neureiter D, Kandler G, Vogt S, Hutter J, Strasser G, Greil R, Hartmann TN, Hopfinger G.

Leuk Lymphoma. 2015;56(8):2465-7. doi: 10.3109/10428194.2014.999328. Epub 2015 Feb 9. No abstract available.

PMID:
25547652
25.

CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms.

Hutterer E, Asslaber D, Caldana C, Krenn PW, Zucchetto A, Gattei V, Greil R, Hartmann TN.

Br J Haematol. 2015 Apr;169(2):286-9. doi: 10.1111/bjh.13188. Epub 2014 Oct 17. No abstract available.

26.

CLL cells under flow.

Hartmann TN.

Blood. 2014 Jun 5;123(23):3533-4. doi: 10.1182/blood-2014-04-565358. No abstract available.

27.

The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.

Girbl T, Lunzer V, Greil R, Namberger K, Hartmann TN.

Transfusion. 2014 Sep;54(9):2325-35. doi: 10.1111/trf.12632. Epub 2014 Mar 28.

28.

Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.

Gassner FJ, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, Rebhandl S, Catakovic K, Hartmann TN, Greil R, Geisberger R.

Haematologica. 2014 May;99(5):67-9. doi: 10.3324/haematol.2013.098459. Epub 2014 Feb 21. No abstract available.

29.

Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells.

Hofbauer SW, Krenn PW, Ganghammer S, Asslaber D, Pichler U, Oberascher K, Henschler R, Wallner M, Kerschbaum H, Greil R, Hartmann TN.

Blood. 2014 Apr 3;123(14):2181-8. doi: 10.1182/blood-2013-08-523563. Epub 2014 Feb 5.

30.

Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.

Grössinger EM, Weiss L, Zierler S, Rebhandl S, Krenn PW, Hinterseer E, Schmölzer J, Asslaber D, Hainzl S, Neureiter D, Egle A, Piñón-Hofbauer J, Hartmann TN, Greil R, Kerschbaum HH.

Leukemia. 2014 Apr;28(4):954-8. doi: 10.1038/leu.2014.37. Epub 2014 Jan 20. No abstract available.

PMID:
24441290
31.

The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia.

Brachtl G, Piñón Hofbauer J, Greil R, Hartmann TN.

Ann Hematol. 2014 Mar;93(3):361-74. doi: 10.1007/s00277-013-1967-y. Epub 2013 Nov 28. Review.

32.

CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.

Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E, Pozzo F, Bomben R, Dal Bo M, D'Arena G, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Rossi D, Gaidano G, Del Poeta G, Gattei V.

Blood. 2013 Nov 7;122(19):3317-21. doi: 10.1182/blood-2013-06-507335. Epub 2013 Sep 25.

33.

Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go?

Asslaber D, Grössinger EM, Girbl T, Hofbauer SW, Egle A, Weiss L, Greil R, Hartmann TN.

Br J Haematol. 2013 Mar;160(5):711-4. doi: 10.1111/bjh.12151. Epub 2012 Dec 4. No abstract available.

PMID:
23205585
34.

CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility.

Girbl T, Hinterseer E, Grössinger EM, Asslaber D, Oberascher K, Weiss L, Hauser-Kronberger C, Neureiter D, Kerschbaum H, Naor D, Alon R, Greil R, Hartmann TN.

Cancer Res. 2013 Jan 15;73(2):561-70. doi: 10.1158/0008-5472.CAN-12-2749. Epub 2012 Nov 1.

35.

Canonical and noncanonical Hedgehog/GLI signaling in hematological malignancies.

Aberger F, Kern D, Greil R, Hartmann TN.

Vitam Horm. 2012;88:25-54. doi: 10.1016/B978-0-12-394622-5.00002-X. Review.

PMID:
22391298
36.

Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?

Jöhrer K, Hofbauer SW, Zelle-Rieser C, Greil R, Hartmann TN.

Expert Opin Biol Ther. 2012 Apr;12(4):425-41. doi: 10.1517/14712598.2012.664128. Epub 2012 Feb 15. Review.

PMID:
22332909
37.

Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells.

Brachtl G, Sahakyan K, Denk U, Girbl T, Alinger B, Hofbauer SW, Neureiter D, Hofbauer JP, Egle A, Greil R, Hartmann TN.

PLoS One. 2011;6(8):e23758. doi: 10.1371/journal.pone.0023758. Epub 2011 Aug 18.

38.

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

Gassner FJ, Weiss L, Geisberger R, Hofbauer JP, Egle A, Hartmann TN, Greil R, Tinhofer I.

Cancer Immunol Immunother. 2011 Jan;60(1):75-85. doi: 10.1007/s00262-010-0920-3. Epub 2010 Sep 21.

39.

Modifying akt signaling in B-cell chronic lymphocytic leukemia cells.

Hofbauer SW, Piñón JD, Brachtl G, Haginger L, Wang W, Jöhrer K, Tinhofer I, Hartmann TN, Greil R.

Cancer Res. 2010 Sep 15;70(18):7336-44. doi: 10.1158/0008-5472.CAN-09-4411. Epub 2010 Sep 7.

40.

Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells.

Desch P, Asslaber D, Kern D, Schnidar H, Mangelberger D, Alinger B, Stoecher M, Hofbauer SW, Neureiter D, Tinhofer I, Aberger F, Hartmann TN, Greil R.

Oncogene. 2010 Sep 2;29(35):4885-95. doi: 10.1038/onc.2010.243. Epub 2010 Jul 5.

PMID:
20603613
41.

CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B.

Leick M, Catusse J, Follo M, Nibbs RJ, Hartmann TN, Veelken H, Burger M.

Immunology. 2010 Apr;129(4):536-46. doi: 10.1111/j.1365-2567.2009.03209.x. Epub 2009 Dec 2.

42.

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.

Hartmann TN, Pleyer L, Desch P, Egle A, Greil R.

Discov Med. 2009 Oct;8(42):157-64. Review.

43.

Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Pleyer L, Egle A, Hartmann TN, Greil R.

Nat Rev Clin Oncol. 2009 Jul;6(7):405-18. doi: 10.1038/nrclinonc.2009.72. Epub 2009 Jun 2. Review.

PMID:
19488076
44.

Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer.

Pfeiffer M, Hartmann TN, Leick M, Catusse J, Schmitt-Graeff A, Burger M.

Br J Cancer. 2009 Jun 16;100(12):1949-56. doi: 10.1038/sj.bjc.6605068. Epub 2009 May 19.

45.

Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow.

Hartmann TN, Grabovsky V, Wang W, Desch P, Rubenzer G, Wollner S, Binsky I, Vallon-Eberhard A, Sapoznikov A, Burger M, Shachar I, Haran M, Honczarenko M, Greil R, Alon R.

Cancer Res. 2009 Apr 1;69(7):3121-30. doi: 10.1158/0008-5472.CAN-08-4136. Epub 2009 Mar 17.

46.

A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells.

Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A, Nagler A, Lapidot T, Thelen M, Alon R.

J Leukoc Biol. 2008 Oct;84(4):1130-40. doi: 10.1189/jlb.0208088. Epub 2008 Jul 24.

PMID:
18653785
47.

Human B cells express the orphan chemokine receptor CRAM-A/B in a maturation-stage-dependent and CCL5-modulated manner.

Hartmann TN, Leick M, Ewers S, Diefenbacher A, Schraufstatter I, Honczarenko M, Burger M.

Immunology. 2008 Oct;125(2):252-62. doi: 10.1111/j.1365-2567.2008.02836.x. Epub 2008 Apr 4.

48.

CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.

Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M.

Oncogene. 2005 Jun 23;24(27):4462-71.

PMID:
15806155
49.

The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer.

Hartmann TN, Burger M, Burger JA.

J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):126-30. Review.

PMID:
15471215
50.

Cell-specific measurement of cytosolic glutathione in poplar leaves.

Hartmann TN, Fricker MD, Rennenberg H, Meyer AJ.

Plant Cell Environ. 2003 Jun;26(6):965-975.

Supplemental Content

Loading ...
Support Center